ALK and non-small cell lung carcinoma: In the beginning, we give a general explanation of the NSCLC common treatments and then continue our study by focusing on the targeted therapy of NSCLC, which be discussed separately in the VEGF, KRAS, EGFR, ALK, ROS1, BRAF, RET, MET, NTRK, HER2, HER3, PI3K/AKT/mTORC, PD1, and CTLA-4 related sections.